KCa3.1 channel inhibition sensitizes malignant gliomas to temozolomide treatment

Giuseppina D'Alessandro, Alfonso Grimaldi, Giuseppina Chece, Alessandra Porzia, Vincenzo Esposito, Antonio Santoro, Maurizio Salvati, Fabrizio Mainiero, Davide Ragozzino, Silvia Di Angelantonio, Heike Wulff, Myriam Catalano, Cristina Limatola

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Malignant gliomas are among the most frequent and aggressive cerebral tumors, characterized by high proliferative and invasive indexes. Standard therapy for patients, after surgery and radiotherapy, consists of temozolomide (TMZ), a methylating agent that blocks tumor cell proliferation. Currently, there are no therapies aimed at reducing tumor cell invasion. Ion channels are candidate molecular targets involved in glioma cell migration and infiltration into the brain parenchyma. In this paper we demonstrate that: i) blockade of the calcium-activated potassium channel KCa3.1 with TRAM-34 has co-adjuvant effects with TMZ, reducing GL261 glioma cell migration, invasion and colony forming activity, increasing apoptosis, and forcing cells to pass the G2/M cell cycle phase, likely through cdc2 de-phosphorylation; ii) KCa3.1 silencing potentiates the inhibitory effect of TMZ on glioma cell viability; iii) the combination of TMZ/TRAM-34 attenuates the toxic effects of glioma conditioned medium on neuronal cultures, through a microglia dependent mechanism since the effect is abolished by clodronate-induced microglia killing; iv) TMZ/TRAM-34 co-treatment increases the number of apoptotic tumor cells, and the mean survival time in a syngeneic mouse glioma model (C57BL6 mice implanted with GL261 cells); v) TMZ/TRAM-34 co-treatment reduces cell viability of GBM cells and cancer stem cells (CSC) freshly isolated from patients. Taken together, these data suggest a new therapeutic approach for malignant glioma, targeting both glioma cell proliferating and migration, and demonstrate that TMZ/TRAM-34 co-treatment affects both glioma cells and infiltrating microglia, resulting in an overall reduction of tumor cell progression.

Original languageEnglish (US)
Pages (from-to)30781-30796
Number of pages16
JournalOncotarget
Volume7
Issue number21
DOIs
StatePublished - May 24 2016

Fingerprint

temozolomide
Glioma
Microglia
Cell Movement
Cell Survival
Therapeutics
Neoplasms
Clodronic Acid
Calcium-Activated Potassium Channels
Neoplastic Stem Cells
Poisons
Conditioned Culture Medium

Keywords

  • Apoptosis
  • Ca activated K channels
  • Cell cycle
  • Malignant glioma
  • Migration

ASJC Scopus subject areas

  • Oncology

Cite this

D'Alessandro, G., Grimaldi, A., Chece, G., Porzia, A., Esposito, V., Santoro, A., ... Limatola, C. (2016). KCa3.1 channel inhibition sensitizes malignant gliomas to temozolomide treatment. Oncotarget, 7(21), 30781-30796. https://doi.org/10.18632/oncotarget.8761

KCa3.1 channel inhibition sensitizes malignant gliomas to temozolomide treatment. / D'Alessandro, Giuseppina; Grimaldi, Alfonso; Chece, Giuseppina; Porzia, Alessandra; Esposito, Vincenzo; Santoro, Antonio; Salvati, Maurizio; Mainiero, Fabrizio; Ragozzino, Davide; Di Angelantonio, Silvia; Wulff, Heike; Catalano, Myriam; Limatola, Cristina.

In: Oncotarget, Vol. 7, No. 21, 24.05.2016, p. 30781-30796.

Research output: Contribution to journalArticle

D'Alessandro, G, Grimaldi, A, Chece, G, Porzia, A, Esposito, V, Santoro, A, Salvati, M, Mainiero, F, Ragozzino, D, Di Angelantonio, S, Wulff, H, Catalano, M & Limatola, C 2016, 'KCa3.1 channel inhibition sensitizes malignant gliomas to temozolomide treatment', Oncotarget, vol. 7, no. 21, pp. 30781-30796. https://doi.org/10.18632/oncotarget.8761
D'Alessandro G, Grimaldi A, Chece G, Porzia A, Esposito V, Santoro A et al. KCa3.1 channel inhibition sensitizes malignant gliomas to temozolomide treatment. Oncotarget. 2016 May 24;7(21):30781-30796. https://doi.org/10.18632/oncotarget.8761
D'Alessandro, Giuseppina ; Grimaldi, Alfonso ; Chece, Giuseppina ; Porzia, Alessandra ; Esposito, Vincenzo ; Santoro, Antonio ; Salvati, Maurizio ; Mainiero, Fabrizio ; Ragozzino, Davide ; Di Angelantonio, Silvia ; Wulff, Heike ; Catalano, Myriam ; Limatola, Cristina. / KCa3.1 channel inhibition sensitizes malignant gliomas to temozolomide treatment. In: Oncotarget. 2016 ; Vol. 7, No. 21. pp. 30781-30796.
@article{91f74e32440b4a11a0fa05db4c8a3652,
title = "KCa3.1 channel inhibition sensitizes malignant gliomas to temozolomide treatment",
abstract = "Malignant gliomas are among the most frequent and aggressive cerebral tumors, characterized by high proliferative and invasive indexes. Standard therapy for patients, after surgery and radiotherapy, consists of temozolomide (TMZ), a methylating agent that blocks tumor cell proliferation. Currently, there are no therapies aimed at reducing tumor cell invasion. Ion channels are candidate molecular targets involved in glioma cell migration and infiltration into the brain parenchyma. In this paper we demonstrate that: i) blockade of the calcium-activated potassium channel KCa3.1 with TRAM-34 has co-adjuvant effects with TMZ, reducing GL261 glioma cell migration, invasion and colony forming activity, increasing apoptosis, and forcing cells to pass the G2/M cell cycle phase, likely through cdc2 de-phosphorylation; ii) KCa3.1 silencing potentiates the inhibitory effect of TMZ on glioma cell viability; iii) the combination of TMZ/TRAM-34 attenuates the toxic effects of glioma conditioned medium on neuronal cultures, through a microglia dependent mechanism since the effect is abolished by clodronate-induced microglia killing; iv) TMZ/TRAM-34 co-treatment increases the number of apoptotic tumor cells, and the mean survival time in a syngeneic mouse glioma model (C57BL6 mice implanted with GL261 cells); v) TMZ/TRAM-34 co-treatment reduces cell viability of GBM cells and cancer stem cells (CSC) freshly isolated from patients. Taken together, these data suggest a new therapeutic approach for malignant glioma, targeting both glioma cell proliferating and migration, and demonstrate that TMZ/TRAM-34 co-treatment affects both glioma cells and infiltrating microglia, resulting in an overall reduction of tumor cell progression.",
keywords = "Apoptosis, Ca activated K channels, Cell cycle, Malignant glioma, Migration",
author = "Giuseppina D'Alessandro and Alfonso Grimaldi and Giuseppina Chece and Alessandra Porzia and Vincenzo Esposito and Antonio Santoro and Maurizio Salvati and Fabrizio Mainiero and Davide Ragozzino and {Di Angelantonio}, Silvia and Heike Wulff and Myriam Catalano and Cristina Limatola",
year = "2016",
month = "5",
day = "24",
doi = "10.18632/oncotarget.8761",
language = "English (US)",
volume = "7",
pages = "30781--30796",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "21",

}

TY - JOUR

T1 - KCa3.1 channel inhibition sensitizes malignant gliomas to temozolomide treatment

AU - D'Alessandro, Giuseppina

AU - Grimaldi, Alfonso

AU - Chece, Giuseppina

AU - Porzia, Alessandra

AU - Esposito, Vincenzo

AU - Santoro, Antonio

AU - Salvati, Maurizio

AU - Mainiero, Fabrizio

AU - Ragozzino, Davide

AU - Di Angelantonio, Silvia

AU - Wulff, Heike

AU - Catalano, Myriam

AU - Limatola, Cristina

PY - 2016/5/24

Y1 - 2016/5/24

N2 - Malignant gliomas are among the most frequent and aggressive cerebral tumors, characterized by high proliferative and invasive indexes. Standard therapy for patients, after surgery and radiotherapy, consists of temozolomide (TMZ), a methylating agent that blocks tumor cell proliferation. Currently, there are no therapies aimed at reducing tumor cell invasion. Ion channels are candidate molecular targets involved in glioma cell migration and infiltration into the brain parenchyma. In this paper we demonstrate that: i) blockade of the calcium-activated potassium channel KCa3.1 with TRAM-34 has co-adjuvant effects with TMZ, reducing GL261 glioma cell migration, invasion and colony forming activity, increasing apoptosis, and forcing cells to pass the G2/M cell cycle phase, likely through cdc2 de-phosphorylation; ii) KCa3.1 silencing potentiates the inhibitory effect of TMZ on glioma cell viability; iii) the combination of TMZ/TRAM-34 attenuates the toxic effects of glioma conditioned medium on neuronal cultures, through a microglia dependent mechanism since the effect is abolished by clodronate-induced microglia killing; iv) TMZ/TRAM-34 co-treatment increases the number of apoptotic tumor cells, and the mean survival time in a syngeneic mouse glioma model (C57BL6 mice implanted with GL261 cells); v) TMZ/TRAM-34 co-treatment reduces cell viability of GBM cells and cancer stem cells (CSC) freshly isolated from patients. Taken together, these data suggest a new therapeutic approach for malignant glioma, targeting both glioma cell proliferating and migration, and demonstrate that TMZ/TRAM-34 co-treatment affects both glioma cells and infiltrating microglia, resulting in an overall reduction of tumor cell progression.

AB - Malignant gliomas are among the most frequent and aggressive cerebral tumors, characterized by high proliferative and invasive indexes. Standard therapy for patients, after surgery and radiotherapy, consists of temozolomide (TMZ), a methylating agent that blocks tumor cell proliferation. Currently, there are no therapies aimed at reducing tumor cell invasion. Ion channels are candidate molecular targets involved in glioma cell migration and infiltration into the brain parenchyma. In this paper we demonstrate that: i) blockade of the calcium-activated potassium channel KCa3.1 with TRAM-34 has co-adjuvant effects with TMZ, reducing GL261 glioma cell migration, invasion and colony forming activity, increasing apoptosis, and forcing cells to pass the G2/M cell cycle phase, likely through cdc2 de-phosphorylation; ii) KCa3.1 silencing potentiates the inhibitory effect of TMZ on glioma cell viability; iii) the combination of TMZ/TRAM-34 attenuates the toxic effects of glioma conditioned medium on neuronal cultures, through a microglia dependent mechanism since the effect is abolished by clodronate-induced microglia killing; iv) TMZ/TRAM-34 co-treatment increases the number of apoptotic tumor cells, and the mean survival time in a syngeneic mouse glioma model (C57BL6 mice implanted with GL261 cells); v) TMZ/TRAM-34 co-treatment reduces cell viability of GBM cells and cancer stem cells (CSC) freshly isolated from patients. Taken together, these data suggest a new therapeutic approach for malignant glioma, targeting both glioma cell proliferating and migration, and demonstrate that TMZ/TRAM-34 co-treatment affects both glioma cells and infiltrating microglia, resulting in an overall reduction of tumor cell progression.

KW - Apoptosis

KW - Ca activated K channels

KW - Cell cycle

KW - Malignant glioma

KW - Migration

UR - http://www.scopus.com/inward/record.url?scp=84971569596&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84971569596&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.8761

DO - 10.18632/oncotarget.8761

M3 - Article

C2 - 27096953

AN - SCOPUS:84971569596

VL - 7

SP - 30781

EP - 30796

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 21

ER -